ALPS Medical Breakthroughs ETF SBIO

Medalist Rating as of | See ALPS Investment Hub

Morningstar’s Analysis SBIO

Will SBIO outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in ALPS Medical Breakthroughs ETF's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 29.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Avidity Biosciences Inc Ordinary Shares

3.62 4.2 Mil
Healthcare

Krystal Biotech Inc

3.45 4.0 Mil
Healthcare

Alkermes PLC

3.18 3.7 Mil
Healthcare

Corcept Therapeutics Inc

3.15 3.6 Mil
Healthcare

Immunovant Inc

3.00 3.4 Mil
Healthcare

Crinetics Pharmaceuticals Inc

2.81 3.2 Mil
Healthcare

Arcellx Inc

2.79 3.2 Mil
Healthcare

Denali Therapeutics Inc

2.65 3.0 Mil
Healthcare

Merus NV

2.41 2.8 Mil
Healthcare

MoonLake Immunotherapeutics Class A

2.11 2.4 Mil
Healthcare

Sponsor Center